Felis ISSN 2398-2950

Buprenorphine

Synonym(s): Buprenorphine HCl

Contributor(s): Kyle Braund, John Dodam, Sheilah Robertson, Jo Murrell

Introduction

Name

  • Buprenorphine.

Class of drug

  • Long acting partial opioid antagonist-agonist.
  • Controlled Substance (Schedule 3).

Description

Chemical name

  • [5-alpha,7-alpha(S)]-17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol.
  • 21-cyclopropyl-7-alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine.

Molecular formula

  • C29H41NO4.

Physical properties

  • Colorless, aqueous solution.

Storage requirements

  • <25°C.
  • Protect from light.
  • Discard any solution remaining in opened vial after dose withdrawn.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • May be mixed with acepromazine Acepromazine maleate to produce neuroleptanalgesia for minor procedures or pre-opeative medication.
  • Used to relieve moderate pain.
  • Sedative and euphoric effects less marked than those produced by morphine.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Opioid analgesics

  • Do not use in conjunction with these as it is a partial agonist and will antagonize the effects of full agonists (morphine Morphine, pethidine Pethidine).
  • May potentiate sedative and ventilatory depressant effects of other CNS depressants.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from VetMed Resource and PubMed.
  • Robertson S A, Taylor P M & Sear J W (2003) Systemic uptake of buprenorphine by cats after oral mucosal administration.Vet Rec152, 675-678.
  • Dobbins S, Brown N O & Shofer F S (2002) Comparison of the effects of buprenorphine, oxymorphone hydrochloride and ketoprofen for post-operative analgesia after onychectomy or onychectomy and sterilization in cats.JAAHA38(6), 507-514.
  • Skarda RT, Hubbell JA, Muir WW, Bednarski RM & Mason DE (1996) Sedation and anesthesia in dogs and cats with cardiovascular diseases. III. Ventilation, respiratory monitoring, treatment for postoperative pain.Schweiz Arch Tierheilkd138(6), 312-318. (In German)
  • Piercy AD (1985)Use of buprenorphine hydrochloride.Vet Rec.117(10), 256.

Other sources of information

  • Based on Small Animal Formulary.Tennant, Bryn (1999) 3rd edn. Cheltenham: BSAVA. ISBN: 0 9052 1452 8.
  • Plumb DC (1999) Veterinary Drug Handbook. 3rd edn. Iowa State University Press, Ames. pp 85-87.
  • SIMBADOL (package insert), Florham Park, NJ, Zoetis, 2014.
  • Data on file. Clinical Efficacy (Soft Tissue), 08-30-MC-D-CT-BP, and Clinical Efficacy (Orthopedic), 08-31-MC-D-CT-BP. Zoetis.
  • Freedom of Information Summary, NADA 141-434, SIMBADOL, July 18, 2014. http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM408852.pdf.

ADDED